The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...

Biogen has been in the news recently after longtime partner Sage Therapeutics filed a lawsuit against the company after ...

Biogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.

Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...

Biogen Inc. closed 41.60% below its 52-week high of $246.44, which the company achieved on February 7th.

In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience ...

Biogen (BIIB) and Eisai announced an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as ...

Chris Viehbacher spoke out about the uncertain policy environment for life sciences companies, though he didn't single ...

Biogen and Eisai said they believe that EC's requests can be addressed with existing information, and that no new safety signals have been identified for Leqembi. The U.S. Food and Drug Administration ...